期刊文献+

利拉鲁肽治疗2型糖尿病的临床机制及效果探讨

下载PDF
导出
摘要 目的探讨利拉鲁肽治疗2型糖尿病的临床机制及效果。方法选取我院收治的120例2型糖尿病患者,将其随机分为观察组和对照组各60例,观察组采用利拉鲁肽治疗,对照组采用格列美脲治疗,比较两组患者治疗后糖化血红蛋白水平、体重及不良反应情况。结果观察组治疗后糖化血红蛋白水平下降明显,且与对照组比较有明显差异P<0.01,两组治疗后患者体重比较也有明显差异P<0.01,观察组治疗后不良反应较对照组明显减少P<0.05。结论利拉鲁肽治疗2型糖尿病可明显降低血糖,减轻患者体重,且不良反应少,值得临床推广使用。
作者 聂其如
机构地区 桃源县人民医院
出处 《中国医学工程》 2013年第5期132-133,共2页 China Medical Engineering
  • 相关文献

参考文献4

二级参考文献22

  • 1刘丽,刘敏涓.2型糖尿病血管病变患者C反应蛋白、纤维蛋白原、D二聚体检测的意义[J].血栓与止血学,2007,13(2):60-61. 被引量:16
  • 2Rothwell PM, Howard SC, Power DA, et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke, 2004,35 ( 10 ) : 2300-2305.
  • 3Drucker D, Nouck M. The incretin system: glucagon - like peptide - 1 receptor agonistes and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J]. Lancet ,2006, 368 : 1696 - 1699.
  • 4Mudaliar S, Henry RR. Incretin therapies:effects beyond glycemic control [J]. Am Med,2009, 122 ( suppl ):S25 - S36.
  • 5Russell- Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once - daily human GLP - 1 analogue [J]. Mol Cell Endocrinol,2009,297(2) : 137 - 140.
  • 6Joshua J. Differdntial chemistry (structure), mechanism of action, and pharmacology of GLP - 1 receptor agonists and DPP - 4 inhibitors [ J ]. Am Pharm Assoe, 2009,49 (suppl 1 ) : S16 - S29.
  • 7Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once - daily human GLP - 1 analogue, improves pancreatic B - cell function and arginine - stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus [J]. Diabet Med,2008,25(2) : 152- 156.
  • 8Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride montherapy for type 2 diabetes ( LEAD - 3 Mono) : a randomised, 52 -week, phase 3, double - blind, parallel - treatment trial [ J ]. Lancet, 2009,373 :473 -481.
  • 9Marre M, Shaw J, Brandle M, et al. Liraglutide, a once -daily human GLP - 1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes ( LEAD - 1 SU) [J]. Diabet Med,2009,26(3) : 268 -278.
  • 10Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes) - 2 study [ J]. Diabetes Care,2009,32( 1 ) : 84 - 90,.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部